MNG1038
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.490
- MITOTIC_SPINDLE+0.394
- MYC_TARGETS_V1+0.387
- DNA_REPAIR+0.337
- PEROXISOME+0.327
- ANDROGEN_RESPONSE+0.311
- HEME_METABOLISM+0.291
- UNFOLDED_PROTEIN_RESPONSE+0.281
- G2M_CHECKPOINT+0.265
- OXIDATIVE_PHOSPHORYLATION+0.233
Top 10 suppressed
- PANCREAS_BETA_CELLS-0.379
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.359
- ANGIOGENESIS-0.272
- ALLOGRAFT_REJECTION-0.253
- TNFA_SIGNALING_VIA_NFKB-0.252
- KRAS_SIGNALING_DN-0.248
- COAGULATION-0.225
- HYPOXIA-0.202
- INFLAMMATORY_RESPONSE-0.190
- P53_PATHWAY-0.186
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 10EE3CFC-9230-40BA-9C9F-77949BA763CC | — | — | 0.896 |
| 2 | R122 | — | — | 0.874 |
| 3 | MNG1053 | — | — | 0.867 |
| 4 | 63204446-7AA0-40DC-996D-440F4E19AD0F | — | — | 0.864 |
| 5 | 24F914FE-3DF0-4286-9231-9D525A777306 | — | — | 0.856 |
| 6 | 15824B66-5519-459A-B0C2-6EABAEEC2D8A | — | — | 0.845 |
| 7 | MNG434 | — | — | 0.843 |
| 8 | SRR934941 | — | — | 0.842 |
| 9 | MNG328 | — | — | 0.841 |
| 10 | SRR934969 | — | — | 0.830 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 28 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.490 | Remibrutinib | — uncovered |
| MITOTIC_SPINDLE | 0.394 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.387 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.337 | Idelalisib | — uncovered |
| PEROXISOME | 0.327 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.311 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.291 | Temsirolimus | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.281 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.265 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.233 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.230 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.227 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.226 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.206 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.193 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.190 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.182 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.175 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.167 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.162 | Inavolisib | — uncovered |